Old Web
English
Sign In
Acemap
>
authorDetail
>
A. Reginald Waldeck
A. Reginald Waldeck
Bayer
Medicine
Prostate cancer
Oncology
Internal medicine
Apalutamide
5
Papers
14
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world study.
2021
Journal of Clinical Oncology
Shan Jiang
Della Varghese
Sreevalsa Appukkuttan
Shelby Corman
Nehemiah Kebede
Kajan Gnanasakthy
Cynthia Macahilig
A. Reginald Waldeck
Arif Hussain
Show All
Source
Cite
Save
Citations (0)
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
2021
The Journal of Urology
Susan Halabi
Shan Jiang
Emi Terasawa
Viviana Garcia-Horton
Rajeev Ayyagari
A. Reginald Waldeck
Neal D. Shore
Show All
Source
Cite
Save
Citations (2)
Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
2020
Journal of Clinical Oncology
Shan Jiang
Emi Terasawa
Viviana Garcia-Horton
Rajeev Ayyagari
A. Reginald Waldeck
Susan Halabi
Neal D. Shore
Show All
Source
Cite
Save
Citations (3)
1